Eisai Co., Ltd. (TYO: 4523)
Japan
· Delayed Price · Currency is JPY | Market Cap | 1.19T |
| Revenue (ttm) | 753.22B |
| Net Income (ttm) | 40.97B |
| Shares Out | 281.89M |
| EPS (ttm) | 143.32 |
| PE Ratio | 29.49 |
| Forward PE | 23.67 |
| Dividend | 160.00 (3.77%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 574,000 |
| Average Volume | 1,469,180 |
| Open | 4,251.00 |
| Previous Close | 4,240.00 |
| Day's Range | 4,226.00 - 4,275.00 |
| 52-Week Range | 4,195.00 - 7,151.00 |
| Beta | -0.13 |
| RSI | 38.62 |
| Earnings Date | Feb 7, 2025 |
About Eisai
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a... [Read more]
Financial Performance
In 2023, Eisai's revenue was 741.75 billion, a decrease of -0.36% compared to the previous year's 744.40 billion. Earnings were 42.41 billion, a decrease of -23.50%.
Financial StatementsNews
Biogen, Eisai say injectable Alzheimer’s therapy granted FDA review
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
TOKYO--(BUSINESS WIRE)-- #IVD--Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), a wholly-owned subsidiary of H.U. Group Holdings, Inc. (Chairman, President and...
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
TOKYO, Dec 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received approval for "URECE(R)" (generic name: dotinurad) from the National Medical Products Administration in China...
Biogen Inc (BIIB) and Eisai's Alzheimer's Drug LEQEMBI Approved in Mexico
Biogen Inc (BIIB) and Eisai's Alzheimer's Drug LEQEMBI Approved in Mexico
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Needham downgraded Biogen Inc (NASDAQ: BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug Leqembi’s (lecanemab) sales growth is expected to stay gradual without a sh...
Eisai wins orphan drug status for Lenvima for esophageal cancer
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachuset...
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai — reversing an...
Biogen gains as Eisai wins EU nod for Alzheimer’s drug
EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen
The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the treatm...
EU Backs Eisai Alzheimer’s Drug Despite Earlier Rejection
Eisai Co. and its partners won the European Union regulator’s backing for use of its Alzheimer’s drug Leqembi in a surprising reversal of a previously negative opinion.
Eisai: Still Relatively Modest Market-Implied Expectations For Leqembi
Q2 2025 Eisai Co Ltd Earnings Presentation Transcript
Q2 2025 Eisai Co Ltd Earnings Presentation Transcript
Eisai Co., Ltd. (ESALF) Q2 2025 Earnings Call Transcript
Eisai Co., Ltd. 2025 Q2 - Results - Earnings Call Presentation
Eisai reports HY results
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
STOCKHOLM , Nov. 7, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs from...
Biogen partner Eisai completes FDA submissions for injectable Alzheimer’s therapy
Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
TOKYO and CAMBRIDGE, Mass. , Oct. 31, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") and Biogen Inc. (NASDAQ: BIIB , Corporate headquarters: Cambridge, Massach...
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
STOCKHOLM , Oct. 31, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Applicat...
Leqembi® revenue totaled JPY 10 billion in the third quarter 2024
STOCKHOLM , Oct. 30, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2024, in co...
Eisai will request reconsideration of initial decision for lecanemab in Australia
STOCKHOLM , Oct. 16, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public stat...
Merck Keytruda with Eisai’s Lenvima succeeds in late-stage trial for liver cancer
Merck's (MRK) Keytruda in combination with Eisai's (ESALY) Lenvima hit main goal ina late-stage trial for liver cancer. Read more here.
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
In the Phase 3 LEAP-012 trial, KEYTRUDA plus LENVIMA in combination with TACE reduced the risk of disease progression or death by 34% compared to TACE alone Late-breaking first interim analysis result...
Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges
Biogen Inc. (NASDAQ: BIIB) and Eisai Ltd’s (OTC: ESALY) Alzheimer’s drug Leqembi (lecanemab) is reportedly offering hope for patients in the early stages of the disease despite it not being a cure. ...